Selected publications
-
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Journal of Clinical Oncology.
2014
Academic Article
GET IT
Times cited: 86 -
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: A multicenter phase II trial.
Journal of Clinical Oncology.
2012
Academic Article
GET IT
Times cited: 118 -
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
Blood.
2012
Academic Article
GET IT
Times cited: 171 -
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Journal of Clinical Oncology.
2003
Academic Article
GET IT
Times cited: 1655 -
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
New England Journal of Medicine.
2002
Academic Article
GET IT
Times cited: 3169 -
Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma.
Cancer.
1999
Academic Article
GET IT
Times cited: 9